Nicole Kulisek

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

William J. Sandborn, Geert D’Haens, Bruce E. Sands et al. · Journal of Crohn s and Colitis · 2022 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

Séverine Vermeire, Chinyu Su, Nervin Lawendy et al. · Journal of Crohn s and Colitis · 2020 · 67 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure

Julián Panés, Geert D’Haens, Bruce E. Sands et al. · United European Gastroenterology Journal · 2024 · 32 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Kevin Winthrop, Séverine Vermeire, Millie D. Long et al. · Inflammatory Bowel Diseases · 2022 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program

Marla C. Dubinsky, Fernando Magro, Flávio Steinwurz et al. · Inflammatory Bowel Diseases · 2022 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17